Bradford K. Amman - 31 Jul 2026 Form 4 Insider Report for Vivos Therapeutics, Inc. (VVOS)

Reporting relationship: Principal Accounting Officer
Issuer ticker: VVOS
Reported as of: 31 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Aug 2026, 16:10:16 UTC
Prior SEC filing: 27 Nov 2024
Source filing: View source filing
Reporting owner signature: /s/ Bradford K. Amman

Key filing fact

Bradford K. Amman filed Form 4 for Vivos Therapeutics, Inc. (VVOS) on 26 Aug 2026.

Key facts

This page summarizes Bradford K. Amman's Form 4 filing for Vivos Therapeutics, Inc. (VVOS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 26 Aug 2026, 16:10.

Change

Previous filing in this sequence was filed on 27 Nov 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001425339 Primary reporting owner

Amman Bradford K.

Relationship: Principal Accounting Officer
Address: 7921 SOUTHPARK PLAZA,, SUITE 210, LITTLETON
Signature: /s/ Bradford K. Amman
Signature date: 26 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VVOS transaction

Common Stock

Award

Transaction value
Shares: +250,000
Change %: +312500%
Price: $0.4100^*
Shares after: 250,080
Date: 31 Jul 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VVOS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +150,000
Change %: +85%
Price: $0.4100^*
Shares after: 326,533
Date: 31 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,000
Exercise price: $0.4100
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

On July 31, 2026 (the "Grant Date"), the Reporting Person received a grant of 150,000 stock options, which grant was made under the Issuer's 2024 Omnibus Equity Incentive Plan. Stock options shall vest and become exercisable at the rate of 25,000 shares per month from November 1, 2026 through April 1, 2026.